Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer

Inclusion Criteria: 1. Signed informed-consent form; 2. Age no less than 18 years; 3. Histologically confirmed locally advanced or metastatic squamous lung cancer; 4. Eastern Cooperative Oncology Group (ECOG) 0-2 with life expectation of no less than 12 weeks; 5. RECIST measurable lesions; 6. Disease progression after failure of platinum-based doublet therapy; 7. Adequate liver/renal/bone marrow function; 8. Human Chorionic Gonadotropin (HCG) test negative for female with contraception measures until 3 months after study end; 9. Compliance, and can be followed up regularly. Exclusion Criteria: 1. Pregnant or breast-feeding female, or not willing to take contraception measures during study; 2. Radiotherapy within 30 days, systematic therapy within 21 days; 3. Serious infection requiring antibiotics intervention during recruitment; 4. Allergic to study drug; 5. Require concurrent biological target therapy; 6. More than grade 1 neuropathy; 7. Uncontrolled brain metastasis or mental illness; 8. Congestive heart failure, uncontrolled cardiac arrhythmia, etc; 9. Other malignancy within 5 years; 10. Can't be followed up or obey protocol; 11. Ineligible by the judge of the investigator.